Gynecomastia Effects Of Certain SARMS And Peptides

Gynecomastia Effects Of Certain SARMS And Peptides

Gynecomastia is a disorder where the breast tissue in men enlarges due to an imbalance in hormones. This can occur during puberty and to a lesser extent in adulthood, as a result of hormone therapy or other underlying diseases.

In many cases, the breast tissue enlarges only slightly, and is barely noticeable. In muscular men it is even harder to detect as it can just blend in with the increased size in chest muscles.

However, if ignored, then the enlarging effect can become worse resulting in very noticeable changes.

Some SARMs and Peptide drugs have shown in clinical testing that their hormone effects actually result in varying degrees of gynecomastia. On this page we will take a look at some of those studies to see what the actual findings were.

What Studies Have Shown

Extensive trials using SARMs and peptide based drugs like MK677, Andarine and GHRP have been conducted to specifically identify the negative effects and any long term impacts to other areas of the body.

Growth hormone (GH) related therapies have long been studied using steroids and testosterone. But these treatments have often been very disruptive and prone to significant side effects.

SARMs and peptides on the other hand, have far more targeted tissue effects, but this has often led to a lower level of understanding of what the longer term side effects might be. In the following research studies we aim to identify the observed results in regards to gynecomastia.

Study 1 Results

The first study of interest was conducted by College of Pharmacy, The Ohio State University in 2005 and looked at the overall therapy options for selective androgen receptor modulators (SARMs).

The research paper was designed to look at the test results from multiple clinical and lab trials in order to identify common effects. Particular attention was paid to those results affecting men, with measurements on bone and muscle mass, as well as overall body complexion.

At the time, many of the positive effects were already identified, especially in regards to therapy options for muscle and bone wasting. The increased levels of growth hormone (GH) production triggered significant increases in muscle tissue as well as bone density.

However, some other hormonal impacts were identified where the effects were not initially that clear.

To identify the wider ranging effects, the researchers looked at trial results that were conducted to test hormonal male contraception. The drugs used in these trials had the most significant effects on levels of testosterone and estrogen.

While there were no major toxic issues, it was noted that increases in breast tissue were very common due to the fluctuations and peaks of hormone levels. Two of the drugs used in the trials were Andarine and Ligandrol. However, further research was recommended to identify the dosage dependent effects on breast tissue.

Study 2 Results

The next research study we want to highlight was conducted between Madigan Health Care System and University of Washington School of Medicine in 2013. The specific focus point was the use of hormone therapy to treat patients with growth hormone deficiency.

Such a deficiency can lead to serious issues including muscle and bone wasting and mostly affects elderly patients where hormonal imbalances have occurred due to aging or disease.

The researchers first identified successful therapies where careful dosage calculations resulted in the reversal of the negative GH levels and ultimately to increases in muscle mass and bone density.

A careful identification of side effects related to the most commonly used GH therapies was achieved by researching all the known clinical trials on many different types of hormone treatments. These included SARMs and peptide drugs that have proven to be highly effective.

What the researchers found is that when it comes to boosting GH levels there are some very commonly observed side effects. While most of them are not serious, there are some that can gradually get worse with time.

The authors specifically identified gynecomastia as a very commonly reported side effect in healthy adults. Some of the trials had revealed a gradual worsening of this condition the longer the drug exposure lasted.

To gain a clearer understanding of this effect, the recommendation is to perform highly dosage specific measurements to better observe what levels and time frames are safer for GH treatment.

Study 3 Results

The final study to highlight was conducted by medical researchers from Mount Sinai Medical Center and University of Washington School of Medicine. The aim here was to research the effects of GH therapy in different age ranges.

While GH levels most commonly drop with natural aging, there are diseases and hormonal problems that can occur in young children and teenagers. When this remains untreated it results in long term effects on the body’s ability to grow into adulthood.

GH therapies in various forms have been conducted over many years. But an overall quantification of these studies had not been conducted. So the authors took an approach of identifying all the known side effects across multiple different drug trials and combine the data to gain a better overall understanding.

While GH boosting therapies have several side effects that can be concerning, gynecomastia was not one of the most prevalent. However, an increase in breast tissue was observed in 12% of drug trial participants across 3 different drugs.

This did highlight the fact that there was a direct correlation and more research would be required in order to completely understand which drugs are most prone to dosage and length of treatment dependent increases in breast tissue.


While gynecomastia is not a serious side effect, it can result in quite enlarged breast tissue in men. When it comes to hormone treatment, a better understanding is required to be able to predict the likelihood of the condition affecting patients.

Because the trial patient’s that observed enlarged breast tissue was quite small, further testing will also need to be conducted on age ranges and subjects with and without different forms of hormone imbalances to fully understand how this effect is triggered.